文献速递骨质疏松与钙磷/甲状旁腺垂体与肾上腺疾病

FCH-PET/CT在原发性甲状旁腺功能亢进症伴MIBI显像与超声不一致或阴性中的应用

FCH-PET/CT in Primary Hyperparathyroidism With Discordant/Negative MIBI Scintigraphy and Ultrasonography.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

本研究为纵向回顾性队列,纳入109例因骨质疏松转诊、伴轻度生物学原发性甲状旁腺功能亢进症的患者,按总血清钙和离子钙分为三组,评估FCH-PET/CT的敏感性与特异性。FCH-PET/CT敏感性在高钙血症组为67%、总钙正常而离子钙升高组为48%、总钙与离子钙均正常组为33%,特异性为97%至99%。

要点

  • FCH-PET/CT敏感性在高钙血症组为67%,总钙正常而离子钙升高组为48%(P = .05 vs 高钙血症组),总钙与离子钙均正常组为33%(P = .004 vs 高钙血症组)。
  • FCH-PET/CT特异性为97%至99%。
  • 在常规影像阴性患者中FCH-PET/CT阳性者为64.3%,其中甲状旁腺切除术后77.8%患者生化缓解。

核心结论

  • 本研究强调FCH-PET/CT在表型明确的血糖正常型原发性甲状旁腺功能亢进症且[99mTc]Tc-甲氧基异丁基异腈显像与超声不一致或阴性患者中的贡献。
  • 然而,血糖正常型原发性甲状旁腺功能亢进症中影像阴性并不排除由经验丰富外科医生实现手术治愈的可能。

研究设计与样本

  • 纵向回顾性队列研究,纳入因骨质疏松转诊、伴轻度生物学原发性甲状旁腺功能亢进症的患者。
  • 共分析109例原发性甲状旁腺功能亢进症患者,按总血清钙和离子钙分为三组:高钙血症组32例、总钙正常而离子钙升高组39例、总钙与离子钙均正常组38例。
  • 所有患者均有生化随访以确认甲状旁腺切除术后是否成功。

主要发现

  • FCH-PET/CT敏感性在高钙血症组为67%,在总钙正常而离子钙升高组为48%(P = .05 vs 高钙血症组),在总钙与离子钙均正常组为33%(P = .004 vs 高钙血症组)。
  • FCH-PET/CT特异性为97%至99%。
  • FCH-PET/CT在常规影像阴性患者中阳性者为64.3%,这些患者甲状旁腺切除术后77.8%实现生化缓解。
  • 20例患者出现三重影像阴性,其中85%患者原发性甲状旁腺功能亢进症缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The contribution of [18F]F-fluorocholine (FCH)-positron emission tomography (PET)/computed tomography (CT) in normocalcemic primary hyperparathyroidism (nPHPT) remains unknown. OBJECTIVE: To evaluate the sensitivity and specificity of FCH-PET/CT in a cohort of osteoporotic patients with nPHPT and discordant or negative [99mTc]Tc-sestamibi scintigraphy and ultrasonography who all underwent parathyroidectomy (PTX). DESIGN: Longitudinal retrospective cohort study in patients referred for osteoporosis with mild biological primary hyperparathyroidism. SETTING: Tertiary referral center with expertise in bone metabolism and surgical management of hyperparathyroidism. PATIENTS: Among 109 patients with PHPT analyzed, 3 groups were individualized according to total serum calcium (tCa) and ionized calcium (iCa): 32 patients with hypercalcemia (HtCa group), 39 patients with normal tCa and elevated iCa (NtCa group), and 38 patients with both normal tCa and iCa (NiCa). All patients had biochemical follow-up confirming or not the success of PTX. MAIN OUTCOME MEASURES: To evaluate the performance of FCH-PET/CT in terms of sensitivity and specificity, and to compare with first-line imaging procedures in the setting of nPHPT. RESULTS: The sensitivity of FCH-PET/CT was 67% in the hypercalcemic group, 48% in the NtCa group (P = .05 vs HtCa), and 33% in the NiCa group (P = .004 vs HtCa). Specificity ranged from 97% to 99%. FCH-PET/CT was positive in 64.3% of patients with negative conventional imaging, with biochemical resolution after PTX in 77.8% of patients. Triple negative imaging was observed in 20 patients, with PHPT resolution in 85% of these patients. CONCLUSION: This study highlights the contribution of FCH-PET/CT in a well-phenotyped cohort of normocalcemic patients with discordant or negative findings in [99mTc]Tc-sestamibi scintigraphy and ultrasonography. However, negative imaging in nPHPT does not rule out the possibility of surgical cure by an experienced surgeon.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Koumakis E, Gauthé M, Martinino A, et al. FCH-PET/CT in Primary Hyperparathyroidism With Discordant/Negative MIBI Scintigraphy and Ultrasonography. J Clin Endocrinol Metab. 2023. PMID: 36750257. doi:10.1210/clinem/dgad073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。